Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).

J Immunother Cancer · 2021 · PMC8693086 · PMID 34933967

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

6 In the POLARIS-02 study with 190 patients, 7 the ORRs were 27.1% and 19.4% in patient populations with PD-L1+ and PD-L1− R/M-NPC, and the difference still did not reach statistical significance either.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.